The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a ...

AstraZeneca (LSE:AZN) recently announced the U.S. FDA accelerated approval of Datroway for treating advanced EGFR-mutated non ...

Like many other major pharmaceutical companies, AstraZeneca is facing a series of patent cliffs for key treatments in its ...

AstraZeneca & Daiichi Sankyo’s Datroway gets US approval for patients with previously treated advanced EGFR-mutated NSCLC ...

Cambridge-based AstraZeneca looks like it has set another drug on its way to blockbuster status - Datroway for the treatment ...

The US Food and Drug Administration (FDA) has approved AstraZeneca and Daiichi Sankyo's Datroway (Datopotamab deruxtecan) for ...

AstraZeneca AZN announced that the FDA has expanded the label of its cancer drug Datroway for a second indication — non-small ...

The FDA has blessed AstraZeneca and Daiichi Sankyo’s Datroway to treat patients with locally advanced or metastatic epidermal ...

FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response ...

AstraZeneca and Daiichi Sankyo's TROP2-directed antibody-drug conjugate (ADC) Datroway has been granted accelerated approval ...

AstraZeneca's Datroway drug has been approved in the U.S. to treat adult patients with non-small cell lung cancer. The British pharmaceutical company said Tuesday that the drug has been approved ...